Clinical trial
A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK44459 Tablets in Subjects With Idiopathic Pulmonary Fibrosis
NCT06764862 is registered in ClinicalTrials.gov with Haisco Pharmaceutical Group Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK44459 Tablets in Subjects With Idiopathic Pulmonary Fibrosis
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 17, 2025
- Completion date
- March 4, 2026
- Enrollment
- 186 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.